Shanghai Allist Pharmaceuticals (688578) Fundamentals 2026 — P/E 24.5x, Revenue Analysis | SniperIQ
Shanghai Allist Pharmaceuticals (688578) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥59.0B, trading at ¥131.22 on the SHH. This SniperIQ fundamentals page covers Shanghai Allist Pharmaceuticals's valuation (P/E 24.5x, P/B 7.6x), profitability (net margin 42.6%), revenue (¥5.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shanghai Allist Pharmaceuticals's market cap?
Shanghai Allist Pharmaceuticals (688578) has a market capitalization of approximately ¥59.0B, trading at ¥131.22 on the SHH. Market cap moves with the live share price.
What is Shanghai Allist Pharmaceuticals's P/E ratio?
Shanghai Allist Pharmaceuticals's trailing twelve-month P/E ratio is 24.5x, with a price-to-book (P/B) of 7.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shanghai Allist Pharmaceuticals?
Shanghai Allist Pharmaceuticals runs a net profit margin of 42.6%, a gross margin of 96.3%, and an operating margin of 49.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shanghai Allist Pharmaceuticals generate?
Shanghai Allist Pharmaceuticals reported revenue of ¥5.2B for fiscal year 2025, with net income of ¥2.2B and earnings per share (EPS) of 4.85. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shanghai Allist Pharmaceuticals pay a dividend?
Shanghai Allist Pharmaceuticals offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shanghai Allist Pharmaceuticals financially healthy?
Shanghai Allist Pharmaceuticals carries a debt-to-equity ratio of 0.00x and a current ratio of 5.25x, with a market beta of 0.11. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shanghai Allist Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai Allist Pharmaceuticals (688578) the key facts are: market cap ¥59.0B, P/E 24.5x, revenue ¥5.2B, 52-week range 78.82-138.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shanghai Allist Pharmaceuticals's full fundamentals live
Get Shanghai Allist Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.